James William Rogers Sells 10,084 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 10,084 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $595,460.20. Following the sale, the chief financial officer directly owned 101,166 shares in the company, valued at $5,973,852.30. This represents a 9.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

James William Rogers also recently made the following trade(s):

• On Thursday, December 11th, James William Rogers sold 19,966 shares of Tempus AI stock. The shares were sold at an average price of $73.20, for a total transaction of $1,461,511.20.

Tempus AI Stock Down 2.7%

NASDAQ TEM opened at $58.37 on Friday. The firm has a market cap of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22. Tempus AI, Inc. has a one year low of $36.22 and a one year high of $104.32. The stock’s 50 day simple moving average is $62.35 and its 200 day simple moving average is $73.50. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12.

Analysts Set New Price Targets

Several brokerages recently issued reports on TEM. Robert W. Baird began coverage on shares of Tempus AI in a research report on Tuesday. They set an “outperform” rating and a $59.00 price target on the stock. Mizuho assumed coverage on shares of Tempus AI in a research report on Thursday. They set an “outperform” rating and a $100.00 target price on the stock. HC Wainwright lowered their price target on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. Piper Sandler dropped their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Finally, BTIG Research increased their price objective on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Eight analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $85.92.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Institutional Investors Weigh In On Tempus AI

Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada boosted its stake in Tempus AI by 201.2% in the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock valued at $1,253,000 after acquiring an additional 17,359 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Tempus AI in the 1st quarter valued at $116,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Tempus AI in the 2nd quarter valued at $307,000. Atria Wealth Solutions Inc. bought a new position in shares of Tempus AI in the 2nd quarter worth $214,000. Finally, Allianz Asset Management GmbH grew its stake in shares of Tempus AI by 52.9% during the second quarter. Allianz Asset Management GmbH now owns 10,400 shares of the company’s stock worth $661,000 after purchasing an additional 3,600 shares during the period. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.